- Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
-
Kim YJ, Kim K, Hwang SH, Kim SS, Lee D, Cheong JY, Cho SW
- KMID: 1705208
- Clin Mol Hepatol.
- 2013 Sep;19(3):300-304.
- doi: 10.3350/cmh.2013.19.3.300
BACKGROUND/AIMS: Relapse has been reported after stopping nucleos(t)ide (NUC) therapy in the majority of chronic HBeAg negative hepatitis patients. However, the ideal treatment duration of HBeAg negative chronic hepatitis B... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Outcomes of Lamivudine Therapy in HBeAg Positive Chronic Hepatitis B with Minimally Elevated ALT
-
Han DH, Park NH, Shin JW, Jung SW, Hwang YT, Kim HS, Jeong ID, Bang SJ, Kim DH
- KMID: 760718
- Korean J Hepatol.
- 2007 Jun;13(2):146-156.
BACKGROUND/AIMS: The aim of this study was to compare the efficacy of lamivudine therapy between chronic hepatitis B (CHB) patients, whose ALT levels less than 2 times the upper... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictors of Lamivudine Resistance in Patients with Chronic Hepatitis B Virus Infection
-
Heo J, Cho M, Cho BM, Lee SM, Kim TO, Kim GH, Kang DH, Song GA
- KMID: 760719
- Korean J Hepatol.
- 2007 Jun;13(2):157-165.
BACKGROUND/AIM: Drug resistance is a major concern during nucleos(t)ide analogues therapy in patients with chronic hepatitis B virus (HBV) infections. The aim of this study was to measure the... -
- CITED
-
- Close
- SHARE
-
- Close
